戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed inflammatory loss of graft function after islet cell transplantation.
2 ed its efficacy in a rhesus macaque model of islet cell transplantation.
3 study islet cells in the rat pancreas and in islet cell transplantation.
4 ing of allograft injury in humans undergoing islet cell transplantation.
5  CXCR4-CXL12 axis, to promote engraftment of islet cell transplantation.
6 s significant therapeutic potential in human islet cell transplantation.
7 ll loss is a significant problem in clinical islet cell transplantation.
8 -2 diabetes, and also reduces the success of islet cell transplantation.
9  diabetic rats was reversed by captopril and islet cell transplantation.
10 a means to alleviate limitations surrounding islet cell transplantation.
11  may have practical applications in clinical islet cell transplantation.
12 ting potential treatments for IDDM including islet cell transplantation.
13 oon retrograde transvenous obliteration, and islet cell transplantation.
14 ti-CD154 a unique agent for further study in islet cell transplantation.
15 the consequences of targeting CD45 in murine islet cell transplantation.
16 cular events that might positively influence islet cell transplantation.
17 red a risk factor for liver, intestinal, and islet cell transplantation.
18 e loss of functional islets after allogeneic islet cell transplantation.
19  patients with brittle type 1 diabetes after islet-cell transplantation.
20  use of pseudoislets for genetics, genomics, islet cell transplantation, and studies of intraislet si
21                       Efforts toward routine islet cell transplantation as a means for reversing type
22                               The promise of islet cell transplantation cannot be fully realized in t
23 rectly applicable to ongoing improvements in islet cell transplantation for human diabetes, particula
24            Increasing evidence suggests that islet cell transplantation for patients with type I diab
25 ent in the clinical relevance of intraportal islet cell transplantation for treatment of type 1 diabe
26                                        Human islet cell transplantation from deceased donors is an es
27 cess of sirolimus and low-dose tacrolimus in islet cell transplantation has influenced many transplan
28                                              Islet cell transplantation has limited effectiveness bec
29                                     Clinical islet cell transplantation has resulted in insulin indep
30 istration (FDA) recently endorsed pancreatic islet cell transplantation (ICT) therapy for suboptimall
31 list for islet transplant, (2) T1D following islet cell transplantation (ICT), (3) T2D without hypogl
32 d diabetic, and diabetic groups treated with islet cell transplantation (ICT), protein kinase C (PKC)
33 port the results of the first pilot trial of islet cell transplantation (ICTx) in patients with diabe
34  analysis plans for future pivotal trials of islet cell transplantation in type 1 diabetes.
35 d a rigorous preclinical model of allogeneic islet cell transplantation, incorporating reduced immune
36 n as the Edmonton protocol demonstrates that islet cell transplantation is becoming a therapeutic rea
37                                     Although islet cell transplantation is considered an ideal form o
38              The optimal site for pancreatic islet cell transplantation is presently unclear, althoug
39  blood mononuclear cells into R- mice before islet cell transplantation leads to acute cellular rejec
40 nts with type 1 diabetes of longer duration, islet cell transplantation may be more effective than me
41                                              Islet cell transplantation resulted in normoglycemia wit
42  vs placebo (RR 0.60; 95% CI 0.41-0.86), and islet cell transplantation vs medical therapy (RR 0.25;
43 p in lung, intestine, pancreas, general, and islet cell transplantation were found.